What's Happening?
Gilead Sciences, Inc. announced its participation in the 20th European AIDS Conference (EACS) in Paris, where it will present new scientific data from its HIV research and development programs. The company will showcase the safety profile of twice-yearly
Lenacapavir for PrEP, five-year results from the BICSTaR study, and novel long-acting combination regimens. Gilead's program highlights its commitment to developing HIV prevention and treatment options tailored to individual needs.
Why It's Important?
Gilead's presentations at EACS 2025 underscore its leadership in HIV innovation and its focus on community partnership to help end the HIV epidemic. The data presented could inform future HIV care strategies, offering insights into long-term treatment outcomes and the potential of new prevention methods. This aligns with Gilead's goal of providing solutions for the evolving needs of people affected by HIV globally.
What's Next?
Gilead will continue to explore the treatment needs of women with HIV, long-acting PrEP options, and opportunities to address unmet HIV prevention needs. The company plans to advance its investigational combination regimens to Phase 3 clinical development, aiming to offer new treatment options that address individual preferences and improve patient outcomes.
Beyond the Headlines
Gilead's commitment to scientific innovation and community partnership reflects a broader effort to transform HIV into a treatable, preventable, chronic condition. The company's advances in medical research have helped improve education, expand access, and address barriers to care, contributing to the global goal of ending the HIV epidemic.
